Abstract 220P
Background
Likenesses between fetal and cancerous tissues have been proposed with some of these similarities being conferred by the means of glycosylation. Analysis of genes involved in this process might be helpful to find potential novel targets in colorectal cancer (CRC).
Methods
Publicly available data of CRC patients from TCGA (n=455) were screened for survival differences according to mRNA levels of glycosylation-associated genes, stratifying them into low and high groups for differential gene expression analysis. Cell estimates were analyzed using single-cell RNAseq in publicly available data sets. Using data from the Genomics of Drug Sensitivity in Cancer (GDSC), compounds were screened for differences in treatment response between groups. Data from the CTPAC and COAD SILU study were used to confirm results.
Results
One candidate gene - Fucosyltransferase 1 (FUT1) - was identified that yielded a difference in median overall survival (high: 99.9 mo vs. low: 49.4 mo, p=0.0095). Baseline characteristics between groups showed no significant differences for age, sex, MSI status or TMB. Gene set enrichment analysis revealed upregulation of genes involved in DNA repair systems and downregulation of genes related to immune function (e.g. leukocyte proliferation, leukocyte cell-cell adhesion). Immune cell deconvolution showed negative association between FUT1 levels, B cells and macrophages – conversely, FUT1 levels correlated positively with naïve CD8+ T cells. ScRNAseq revealed high FUT1 mRNA levels in cancer and endothelial cells. FUT1 high tumors were characterized by an activation of MAP kinase, VEGF, TGF-beta, estrogen and PI3K/mTOR signaling, whereas p53, Trail, hypoxia, androgen and NFkB signaling were decreased. Differences in predicted IC50 levels were found for inhibitors of PI3K/mTOR and MAP kinase.
Conclusions
We identified high FUT1 expression as a novel, independent poor prognosticator in CRC. Impaired prognosis might be attributable to changes in DNA repair mechanisms and cell cycle as well as immunogenicity. In silico analysis revealed therapeutic vulnerability towards PI3K/mTOR and MAP kinase inhibition. Validation studies using in vitro methods and an independent clinical trial dataset are currently ongoing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1173P - Combining mass spectrometry with quantitative continuous scoring to unlock the full quantitative potential of immunohistochemistry
Presenter: Ana Hidalgo-Sastre
Session: Poster session 09
1174P - FLAMINGO: Accurate cancer detection from ultra-low-pass whole genome sequencing of cell-free DNA
Presenter: Daan Vessies
Session: Poster session 09
1175P - Universal circulating tumor DNA quantification using deep learning
Presenter: Anders Skanderup
Session: Poster session 09
Resources:
Abstract
1176P - Potential utility of ctDNA to detect false positive PET/CT in the evaluation of lymphoma response
Presenter: Alejandro martín-muñoz
Session: Poster session 09
1177P - FRESH: The Gustave Roussy program to facilitate access to liquid biopsy for precision oncology in France
Presenter: Etienne Rouleau
Session: Poster session 09
1178P - EGFR evaluation in non-small cell lung cancer: An artificial intelligence approach to pre-molecular analysis
Presenter: Chad Vanderbilt
Session: Poster session 09
1179P - WomEC: a novel diagnostic test for the detection of endometrial cancer in uterine fluids
Presenter: Antonio Gil-Moreno
Session: Poster session 09
1180P - An integrated metabolomics-based platform for early-stage detection of multiple cancers
Presenter: imliwati longkumer
Session: Poster session 09
1181P - Diagnostic target product profiles for cancer: A demand signaling tool to stimulate innovation in early cancer diagnosis
Presenter: Sonja Marjanovic
Session: Poster session 09